Vericel (VCEL) Other Accumulated Expenses (2013 - 2026)
Vericel recorded quarterly Other Accumulated Expenses of $116000.0 in Q1 2026, little changed quarter-over-quarter from $116000.0 in Q4 2025, and little changed year-over-year from $116000.0 in Q1 2025.
Vericel's Other Accumulated Expenses history runs 14 years deep, the most recent figure standing at $116000.0 for Q1 2026.
- In Q1 2026, Other Accumulated Expenses changed 0.0% year-over-year to $116000.0; the TTM figure through Mar 2026 stood at $116000.0 (changed 0.0% YoY), while the FY2025 annual figure was $116000.0, changed 0.0% from the prior year.
- Other Accumulated Expenses came in at $116000.0 for Q1 2026 at Vericel, roughly flat from $116000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $118000.0 in Q2 2025 to a low of $20000.0 in Q1 2023.
- A 5-year average of $75250.0 and a median of $78500.0 in 2022 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses changed 0.0% in 2022 and tumbled 51.22% in 2023, its largest moves.
- Vericel's Other Accumulated Expenses stood at $41000.0 in 2022, then slumped by 48.78% to $21000.0 in 2023, then surged by 452.38% to $116000.0 in 2024, then changed by 0.0% to $116000.0 in 2025, then changed by 0.0% to $116000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $116000.0, $116000.0, and $116000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Vericel | 1.69 Bn | 1.55 Bn | 49.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 116,000.00 |
| Dec 31, 2025 | 116,000.00 |
| Sep 30, 2025 | 116,000.00 |
| Jun 30, 2025 | 118,000.00 |
| Mar 31, 2025 | 116,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Jun 30, 2023 | 21,000.00 |
| Mar 31, 2023 | 20,000.00 |
| Dec 31, 2022 | 41,000.00 |
| Sep 30, 2022 | 41,000.00 |
| Jun 30, 2022 | 41,000.00 |
| Mar 31, 2022 | 41,000.00 |
| Dec 31, 2021 | 41,000.00 |
| Sep 30, 2021 | 41,000.00 |
| Jun 30, 2021 | 41,000.00 |
| Mar 31, 2021 | 41,000.00 |
| Dec 31, 2020 | 41,000.00 |
| Sep 30, 2020 | 41,000.00 |
| Jun 30, 2020 | 41,000.00 |
| Mar 31, 2020 | 41,000.00 |
| Dec 31, 2019 | 41,000.00 |
| Sep 30, 2019 | 35,000.00 |
| Jun 30, 2019 | 34,000.00 |
| Mar 31, 2019 | 176,000.00 |
| Dec 31, 2018 | 754,000.00 |
| Sep 30, 2018 | 189,000.00 |
| Jun 30, 2018 | 198,000.00 |
| Mar 31, 2018 | 159,000.00 |
| Dec 31, 2017 | 181,000.00 |
| Sep 30, 2017 | 216,000.00 |
| Jun 30, 2017 | 215,000.00 |
| Mar 31, 2017 | 291,000.00 |
| Dec 31, 2016 | 256,000.00 |
| Sep 30, 2016 | 39,000.00 |
| Jun 30, 2016 | 39,000.00 |
| Mar 31, 2016 | 136,000.00 |
| Dec 31, 2015 | 160,000.00 |
| Sep 30, 2015 | 130,000.00 |
| Jun 30, 2015 | 154,000.00 |
| Mar 31, 2015 | 180,000.00 |
| Dec 31, 2014 | 210,000.00 |
| Dec 31, 2013 | 6,000.00 |